The Global Molecular Imaging Market, by Product Type (Devices: Molecular Ultrasound Imaging, Positron Emission Tomography (PET),    Single Photon Emission Computed Tomography (SPECT), Nuclear Magnetic Resonance (NMR) Spectrometer, and Hybrid Products {Positron Emission Tomography - Computed Tomography (PET-CT), Positron Emission Tomography - Magnetic Resonance (PET-MR), Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT), Single Photon Emission Computed Tomography - Magnetic Resonance (SPECT-MR)} and Software Platforms: On Premises Solutions and Cloud Based Solutions), by Application (Cardiovascular, Neurology, Oncology, Respiratory, Gastrointestinal, and Other Applications), by End Users (Hospitals, Diagnostic Imaging Centres, and Ambulatory Surgical Centres), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 4,309.0 Mn in 2021 and is expected to exhibit a CAGR of 5.4% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Market players are focusing on inorganic activities such as acquisition and collaboration, which is expected to drive the global molecular imaging market growth over the forecast period. For instance, in March 2021, Bruker Corp. a scientific instrument manufacturer announced a partnership with Cambridge Isotope Laboratories (CIL), a leading producer of stable isotopes based in Massachusetts, formalizing a long-term relationship and expanding Bruker's capabilities to deliver end-to-end service solutions in nuclear magnetic resonance (NMR) spectroscopy to its installed customer base under the LabScape brand.

In addition, increasing approvals for newer products is contributing to the market growth. For instance, in June 2021, GE Healthcare, a global medical technology and digital solutions innovator announced the launch of molecular imaging products and solutions at the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2021 summer conference, held in Washington, DC. The products include Nuclear Medicine (SPECT/CT), Discovery MI Gen 2, Radio Pharmacy, and Pharmaceutical Diagnostics & PET Tracers.

Global Molecular Imaging Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared the COVID-19 a pandemic on March 11, 2020. Currently, the spread of COVID-19 is far from over, and various challenges have led to increasing awareness of the public and calling for novel techniques to aid in diagnosis and treatment. Based on the principle of molecular imaging, positron emission tomography (PET) is expected to offer pathophysiological alternations of the COVID-19 in the molecular/cellular perspectives and facilitate the clinical management of patients. This, in turn, is expected to surge the demand for molecular imaging equipment and thereby drive the market growth.

Browse 22 Market Data Tables and 27 Figures spread through 237 Pages and in-depth TOC on “Global Molecular Imaging Market”- Forecast to 2028, Global Molecular Imaging Market, by Product Type (Devices: Molecular Ultrasound Imaging, Positron Emission Tomography (PET),    Single Photon Emission Computed Tomography (SPECT), Nuclear Magnetic Resonance (NMR) Spectrometer, Hybrid Products {Positron Emission Tomography- Computed Tomography (PET-CT), Positron Emission Tomography- Magnetic Resonance (PET-MR), Single Photon Emission Computed Tomography- Computed Tomography (SPECT-CT), Single Photon Emission Computed Tomography- Magnetic Resonance (SPECT-MR)} and Software Platforms: On Premises Solutions and Cloud Based Solutions), by Application (Cardiovascular, Neurology, Oncology, Respiratory, Gastrointestinal and Other), by End Users (Hospitals, Diagnostic Imaging Centres and Ambulatory Surgical Centres), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights related to molecular imaging market, click the link below:

https://www.coherentmarketinsights.com/market-insight/molecular-imaging-market-2191

The increasing adoption of molecular imaging products and rising awareness of early diagnosis are likely to propel the market growth. Moreover, an increase in the usage of integrated technologies such as PET-CT, SPECT-CT, etc. in the diagnosis of various chronic diseases is boosting the demand for molecular imaging products and thereby the market growth.

Key Takeaways of the Global Molecular Imaging Market:

  • The global molecular imaging market is expected to exhibit a CAGR of 5.4% during the forecast period. Change in dietary habits and sedentary lifestyle lead to a surge in the number of patients with various chronic diseases such as cardiovascular, respiratory diseases, etc. This is expected to drive the market growth. For instance, according to the World Health Organization (WHO), in 2019, an estimated 32% of deaths occurred due to cardiovascular diseases globally.
  • Based on product type, the devices segment is estimated to grow with the fastest CAGR in the global molecular imaging market over the forecast period, owing to increasing product launches or approvals. For instance, in October 2015, Lightpoint Medical, an innovative medical device company specializing in imaging technologies, announced that LightPath Imaging System received CE marking, allowing it to be launched in Europe. LightPath Imaging System is intended for use in the operating room to assist surgeons in ensuring that all cancerous tissues are removed in a single operation.
  • Among applications, the oncology segment is estimated to exhibit significant CAGR over the forecast period in the global molecular imaging Increasing adoption of growth strategies such as partnership, collaboration, acquisition etc. to gain the market share is likely drive the growth of segment. For instance, in September 2016, Bruker, an American manufacturer of scientific instruments, announced that it had signed an agreement to acquire the preclinical imaging business of Oncovision, a leading provider of innovative medical imaging devices used for the diagnosis of cancer.
  • In terms of end users, the diagnostic imaging centers segment is expected to exhibit the highest CAGR in the molecular imaging market during the forecast period, due to a strong focus service providers on strengthening the diagnostic services. For instance, in November 2020, the Center for Diagnostic Imaging (CDI), one of the leading outpatient imaging providers in the U.S., announced the acquisition of two established advanced medical imaging groups in Salt Lake City, Utah, the U.S. – Open Imaging and U.S. MRI – resulting in a combined network of eight outpatient imaging centers serving the Utah market.
  • Among regions, Asia Pacific is anticipated to expand at the highest CAGR in the molecular imaging market over the forecast period, as market players are increasingly focusing on inorganic activities such as partnerships, collaboration, acquisition, etc. to expand their business. For instance, in April 2019, ITM Isotopen Technologien München AG, a group of specialized radiopharmaceutical companies, and United Imaging Healthcare Co., Ltd. (UIH), a manufacturer of precision cancer imaging and innovative medical IT solutions, announced that they had signed an agreement to collaborate in the marketing and sales of ITM and UIH imaging and related products to clinical customers in China and other regions.
  • Major players operating in the global molecular imaging market include GE Healthcare, Bruker Corporation, Fujifilm Holdings Corp., Siemens Healthineers, Koninklijke Philips N.V., Canon Medical Systems Corporation, United Imaging Healthcare Co., Ltd., Mediso Kft., Positron Corporation, Esaote SpA, Carestream Health, Mirada Medical Limited, and Hermes Medical Solutions

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo